Trends in Inflammatory Bowel Disease Therapy 1999: The proceedings of a symposium organized by AXCAN PHARMA, held in Vancouver, BC, August 27–29, 1999C. Noel Williams, R.F. Bursey, D.G. Gall, F. Martin, R.S. McLeod, L.R. Sutherland, J.L. Wallace This Trends in Inflammatory Bowel Disease Therapy Symposium was held in Vancouver, British Columbia, Canada, 27~29 August 1999. This is the seventh international symposium, sponsored by Axcan Pharma Canada Inc., since the first symposium in 1986. The Canadian Association of Gastroenterology has co-sponsored these symposia since 1990. Each symposium has been published, and reflects and updates the extensive research and education, and the understanding of the mechanisms and treatment of inflammatory bowel disease. From the beginning, Canadian and international experts have been involved, maintaining a consistently high quality, both in their presentations, during discussions, and the subsequent publication of their work. There have been major advances since the symposium held two years ago, and these are presented in this book. In keeping with modern educational practice, objectives are provided, and all presentations were subject to written independent evalu ation. All participants are asked to declare any conflicts of interest. MOCOMP and educational credits are available. |
Contents
Genetics of inflammatory bowel disease where are we? | 3 |
Genetics of inflammatory bowel disease why is it important? | 13 |
Genetics of IBD impact on immune function | 23 |
Bacterial factors in inflammatory bowel disease pathogenesis | 39 |
Inflammatory bowel disease autoimmunity or chronic inflammation? | 46 |
Neutrophilepithelial interactions and efforts to downregulate them in inflammatory bowel disease | 54 |
Understanding inflammatory bowel disease at the millennium tentative answers and future questions | 61 |
Diagnosis of inflammatory bowel disease an update | 73 |
Risk factors and prevalence of bone disease in inflammatory bowel disease | 147 |
Management of low bone mass in patients with inflammatory bowel disease | 163 |
Steroidinduced osteonecrosis in inflammatory bowel disease Canadian legal status | 173 |
Psychotherapy for inflammatory bowel disease new prospects | 185 |
The use of complementary and alternative medicine by patients with inflammatory bowel disease | 194 |
Gut inflammation is there a role for herbal medicines? | 201 |
The role of nutrition in the treatment of inflammatory bowel disease | 207 |
Antibodies to proinflammatory cytokines | 219 |
Recent developments in the diagnosis and management of paediatric inflammatory bowel disease | 87 |
Inflammatory bowel disease in the elderly | 96 |
Induction of remission in ulcerative colitis | 107 |
Remission maintenance in ulcerative colitis | 117 |
Induction therapy for Crohns disease | 128 |
Maintenance of remission in Crohns disease | 137 |
Other editions - View all
Common terms and phrases
acid active Crohn's disease allele anti-inflammatory antigen antineutrophil cytoplasmic antibodies ASCA associated autoantibodies autoimmune azathioprine bacterial bone loss bone mass bone mineral bowel disease IBD budesonide calcium cDNA chemokine chromosome chronic clinical colonic corticosteroids Crohn's disease cyclosporin cytokines diagnosis diets differential disease activity distal dose down-regulate drugs effects efficacy elderly endoscopic Engl function Gastroenterol Gastroenterology gene expression genetic genome herbal medicines IBD patients identified immune response Immunol increased induce inflammation inflammatory bowel disease infliximab intravenous lesions linkage LXA4 lymphocytes maintenance markers mediators mesalazine mucosal neutrophils oral osteoporosis pANCA pathogenesis pathogens patients with Crohn's patients with IBD patients with inflammatory phenotype placebo plaintiff population postmenopausal potential prednisone present probiotics proinflammatory protein recent receptor rectal recurrence relapse remission resection risk factors role specific steroids sulphasalazine surgery Targan therapeutic therapy treatment ulcerative colitis vitamin vitamin D